Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS) - Thongprasert, S; Duffield, E; Saijo, N (J Thorac Oncol, 2011)
, et al.